The Valley Desk

NCT06995677 · Interventional trial

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Overall registry status Recruiting

Phase 2

Conditions FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration, FGFR3 Gene Fusions, FGFR3 Gene Mutation, Low-grade NMIBC

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov